Prostaglandin synthesis and inflammatory signaling pathways

The prostaglandin synthesis and inflammatory signaling pathways represent a complex network of enzymatic reactions and receptor-mediated events that convert arachidonic acid into potent lipid mediators known as prostanoids. The central enzymes in this pathway are cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), which catalyze the formation of prostaglandin H2, the unstable precursor for all other prostaglandins, prostacyclin, and thromboxanes (Nature Reviews Drug Discovery, 2003). These molecules exert their biological effects by binding to specific G protein-coupled receptors, influencing a wide array of physiological processes including inflammation, pain, fever, and vascular homeostasis (PubMed: PMC3081099). In pathological states, the overproduction of prostaglandins, particularly via the inducible COX-2 isoform, contributes significantly to chronic inflammation, autoimmune diseases, and tumorigenesis. Therapeutic strategies historically focus on inhibiting COX enzymes with nonsteroidal anti-inflammatory drugs (NSAIDs) to alleviate pain and inflammation, though modern approaches also explore targeting specific downstream synthases or receptors to minimize side effects like gastrointestinal or cardiovascular complications (StatPearls: Prostaglandins, 2023).

Other names

Arachidonic acid cascadeEicosanoid biosynthetic pathwayCyclooxygenase pathwayProstanoid signaling pathwayCOX pathway

Inhibition of cyclooxygenase enzymes (COX-1 and COX-2) to prevent the conversion of arachidonic acid into prostaglandin H2 (PGH2); antagonism or agonism of specific prostanoid G protein-coupled receptors such as EP, DP, FP, IP, and TP receptors (StatPearls: NSAIDs, 2023; Pharmacological Reviews, 2011).